BR112023021806A2 - Métodos e composições compreendendo peptídeos mhc classe i - Google Patents

Métodos e composições compreendendo peptídeos mhc classe i

Info

Publication number
BR112023021806A2
BR112023021806A2 BR112023021806A BR112023021806A BR112023021806A2 BR 112023021806 A2 BR112023021806 A2 BR 112023021806A2 BR 112023021806 A BR112023021806 A BR 112023021806A BR 112023021806 A BR112023021806 A BR 112023021806A BR 112023021806 A2 BR112023021806 A2 BR 112023021806A2
Authority
BR
Brazil
Prior art keywords
peptide
compositions
disclosure
methods
peptides
Prior art date
Application number
BR112023021806A
Other languages
English (en)
Inventor
Cassian Yee
Ke Pan
Yulun Chiu
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112023021806A2 publication Critical patent/BR112023021806A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos e composições compreendendo peptídeos de mhc de classe i. a divulgação atual atende a uma necessidade na técnica ao fornecer métodos e composições para tratar e vacinar indivíduos contra o câncer. consequentemente, aspectos da divulgação referem-se a um peptídeo isolado compreendendo pelo menos 70% de identidade de sequência com um peptídeo de seq id no:1 ou 2. em algumas modalidades, o peptídeo compreende pelo menos 6 aminoácidos contíguos de um peptídeo de seq id no:1 ou 2. :1 ou 2. aspectos adicionais referem-se a composições farmacêuticas compreendendo o peptídeo isolado, ácidos nucleicos que codificam o peptídeo e vetores de expressão e células hospedeiras compreendendo os ácidos nucleicos da divulgação. também é fornecida uma célula dendrítica isolada in vitro compreendendo um peptídeo, ácido nucleico ou vetor de expressão da divulgação.
BR112023021806A 2021-04-19 2022-04-18 Métodos e composições compreendendo peptídeos mhc classe i BR112023021806A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163176477P 2021-04-19 2021-04-19
PCT/US2022/025223 WO2022225852A1 (en) 2021-04-19 2022-04-18 Methods and compositions comprising mhc class i peptides

Publications (1)

Publication Number Publication Date
BR112023021806A2 true BR112023021806A2 (pt) 2024-01-23

Family

ID=83722630

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021806A BR112023021806A2 (pt) 2021-04-19 2022-04-18 Métodos e composições compreendendo peptídeos mhc classe i

Country Status (9)

Country Link
EP (1) EP4326306A1 (pt)
JP (1) JP2024517630A (pt)
KR (1) KR20230172572A (pt)
CN (1) CN117425665A (pt)
AU (1) AU2022260281A1 (pt)
BR (1) BR112023021806A2 (pt)
CA (1) CA3217185A1 (pt)
IL (1) IL307802A (pt)
WO (1) WO2022225852A1 (pt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Also Published As

Publication number Publication date
CN117425665A (zh) 2024-01-19
IL307802A (en) 2023-12-01
WO2022225852A1 (en) 2022-10-27
AU2022260281A1 (en) 2023-11-23
JP2024517630A (ja) 2024-04-23
CA3217185A1 (en) 2022-10-27
EP4326306A1 (en) 2024-02-28
KR20230172572A (ko) 2023-12-22

Similar Documents

Publication Publication Date Title
CR20200287A (es) Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
Silverberg et al. The effect of carboxymethylating a single methionine residue on the subunit interactions of glycophorin A
US20140030808A1 (en) Method for Cellular RNA Expression
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
BR112022015897A2 (pt) Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
BR112022015888A2 (pt) Receptores de células t restritos a hla classe i contra ras com mutação g12d
Lyukmanova et al. Human SLURP-1 and SLURP-2 proteins acting on nicotinic acetylcholine receptors reduce proliferation of human colorectal adenocarcinoma HT-29 cells
BR112022016661A2 (pt) Receptores de células t restritos ao hla classe ii contra ras com mutação g12v
BR112021023957A2 (pt) Peptídeos
BR112022019571A2 (pt) Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula
CL2023000426A1 (es) Neoantígenos ras y usos de los mismos
BR112023021806A2 (pt) Métodos e composições compreendendo peptídeos mhc classe i
BR112022026749A2 (pt) Polinucleotídeo isolado, polipeptídeo hexon, capsídeo adenoviral, adenovírus, partícula semelhante a vírus, vetor, composição, célula e método in vitro para a produção de um adenovírus ou de uma partícula semelhante a adenovírus
BR112022012057A2 (pt) Novos métodos de entrega celular
WO2017192761A1 (en) Propionyl-coa carboxylase compositions and uses thereof
Johnson et al. A proteomic analysis of the effect of growth hormone on mammary alveolar cell-T (MAC-T) cells in the presence of lactogenic hormones
Tombes et al. Sea urchin sperm creatine kinase: the flagellar isozyme is a microtubule-associated protein
Ramsden et al. Identification of a Rapidly Labelled 350K Histidine‐Rich Protein in Neonatal Mouse Epidermis
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
CN110078793A (zh) 一种具有抗衰老和修复作用的多肽及其用途
Liu et al. BP5 regulated B cell development promoting anti-oxidant defence
WO2021222633A3 (en) Methods for treating covid-19
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
Alcolea et al. An insight into differential protein abundance throughout Leishmania donovani promastigote growth and differentiation
BRPI0509293A (pt) processo para fazer evoluir uma proteìna x, proteìna n-desoxirribosiltranferase mutada, ácido nucleico, vetor de expressão, célula hospedeira, utilização de uma proteìna, processo de preparação de compostos, e, cepa de e. coli